Research programme: neuroprotective therapeutics - Astrocyte Pharmaceuticals/University of Texas Health Science Center at San Antonio

Drug Profile

Research programme: neuroprotective therapeutics - Astrocyte Pharmaceuticals/University of Texas Health Science Center at San Antonio

Alternative Names: AST 002; AST 003; AST 004

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astrocyte Pharmaceuticals; University of Texas Health Science Center at San Antonio
  • Class Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Brain injuries; Migraine; Neurodegenerative disorders
  • No development reported Stroke

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Brain injuries in USA
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Stroke in USA
  • 28 Jun 2016 Early research in Brain injuries in USA (Sublingual) (Astrocyte Pharmaceuticals pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top